The Role of Nuclear Cardiology in Cardiologist Clinical Practice and What to Expect from a Nuclear Medicine Physician
PDF
Cite
Share
Request
Review
P: 81-89
April 2024

The Role of Nuclear Cardiology in Cardiologist Clinical Practice and What to Expect from a Nuclear Medicine Physician

Nucl Med Semin 2024;10(1):81-89
1. Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Samsun, Türkiye
No information available.
No information available
Publish Date: 05.04.2024
PDF
Cite
Share
Request

ABSTRACT

Cardiovascular disorders remain the leading cause of death in all societies today. The primary cause of this problem among cardiovascular disorders is coronary artery disease (CAD). The identification of CAD requires a clinical evaluation, anamnesis, and basic non-invasive and invasive imaging methods. Today’s current imaging techniques are getting increasingly important due to the advancement of technology. Nuclear cardiology is one of the growing diagnostic improvements in procedures. Diagnosis of CAD, diagnosis and severity of ischemia, prognosis and risk assessment, assessment of left ventricular function, congestive heart failure, hibernation and stunning difference, presence or absence of viability, cardiac amyloidosis, and identification of infected endocarditis, especially in cases with prosthetic valves are among the daily routine applications of nuclear cardiology. Therefore, it is important for Nuclear Medicine specialists to include clear statements and quantitative data in reporting test results that meet the needs of cardiologists. This article will focus on the indications for referring basic cardiovascular diseases to nuclear cardiology and the reporting expectations based on clinical diagnosis.

Keywords:
Nuclear Medicine, cardiology, imaging

References

1
Members TF, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
2
Trägårdh E, Hesse B, Knuuti J, et al. Reporting nuclear cardiology: a joint position paper by the European Association of Nuclear Medicine (EANM) and the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging 2015;16:272-279.
3
Karaca Özer P. Kronik koroner sendromlarda temel testler ve non-invaziv incelemeler. Kudat H, editör. Kronik Koroner Sendromlar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.19-25.
4
Toprak İH, Demirbağ R. Kronik Koroner Sendromlar. Harran Üniversitesi Tıp Fakültesi Dergisi 2023;20:688-694.
5
Members WC, Virani SS, Newby LK, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology 2023;82:833-955.
6
Ural D. Kardiyologların Nükleer Kardiyolojiden Beklentileri. Nucl Med Semin 2018;4:157-162.
7
Yalçın H, Canbaz Tosun F. Koroner arter hastalığı tanı ve yönetiminde nükleer kardiyoloji. Nucl Med Semin 2018;4:80-95.
8
Arslan M, Barutçu A, Arslan ŞF, Duygu A. Non-obstruktif Koroner Arter Hasta Grubunda Miyokardiyal İskeminin Miyokard Perfüzyon Sintigrafisi ve Speckle Tracking Ekokardiyografi ile Değerlendirilmesi. Eskisehir Med J 2022;3:269-275.
9
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020;22:1342-1356.
10
Tanai E, Frantz S. Pathophysiology of heart failure. Compr Physiol 2011;6:187-214.
11
Giubbini R, Milan E, Bertagna F, et al. Nuclear cardiology and heart failure. Eur J Nucl Med Mol Imaging 2009;36:2068-2080.
12
Karaçavuş S, Altun GD. Kalp Yetmezliği ve Aritmilerde Nükleer Kardiyoloji. Nucl Med Semin 2018;4:106-114.
13
Travin MI. Cardiac radionuclide imaging to assess patients with heart failure. Semin Nucl Med 2014;44:294-313.
14
Paterson I, Mielniczuk LM, O’Meara E, So A, White JA. Imaging heart failure: current and future applications. Can J Cardiol 2013;29:317-328.
15
Bravo PE, Bergmark BA, Vita T, et al. Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy. Eur Heart J 2018;39:316-323.
16
Sen F, Demir H, Altun GD, Özdemir E, Özdemir S, Tosun FC. Kardiyak Sarkoidozda F-18 FDG PET/BT ile Enflamasyon Goruntuleme Kilavuzu. Nucl Med Semin 2020;6:211-219.
17
Karaçavuş S. Imaging Modalities Used in Preclinical Studies. Nucl Med Semin 2019;5:23-29.
18
Altun GD, Serim BD, Özdemir E, et al. İyot-123 Meta-iyodobenzilguanidin Kardiyak İnervasyon Görüntüleme Kılavuzu. Nucl Med Semin 2020;6:198-210.
19
Çavuşoğlu Y, Özpelit E, Çelik A, et al. Kardiyak amiloidoz: Tanı ve tedavide yenilikler. Turk Kardiyol Dern Ars 2019;47(Suppl 2):1-34.
20
Murat S, Çavuşoğlu Y, Sivrikoz İA. Sol ventrikül hipertrofisi ve korunmuş ejeksiyon fraksiyonlu kalp yetersizliğinin sıklıkla atlanan ve nadir bir nedeni olan doğal (wild type) transtiretine bağlı kardiyak amiloidoz olgusu. Turk Kardiyol Dern Ars 2021;49:579-584.
21
Simões MV, Fernandes F, Marcondes-Braga FG, et al. Position statement on diagnosis and treatment of cardiac amyloidosis–2021. Arq Bras Cardiol 2021;117:561-598.
22
Kittleson M, Ruberg F, Ambardekar A, Brannagan T, Cheng R. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 2023;81:1076-1126.
23
Fowler Jr VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases criteria for infective endocarditis: updating the modified Duke criteria. Clin Infect Dis 2023;77:518-526.
24
Şimşek-Yavuz S, Akar AR, Aydoğdu S, et al. İnfektif endokarditin tanısı, tedavisi ve önlenmesi: Ulusal uzlaşı raporu. Klinik Derg 2019;32:2.